聚乙二醇干扰素α-2a联合恩替卡韦治疗拉米夫定耐药的慢性乙型肝炎患者疗效分析*

doi:10.3969/j.issn.1672-5069.2017.03.024

Abstract

Zang Wei, Tian Lifeng, Qiu Fang, et al.. Rescue therapy of pegylated interferon α-2a and entecavir in patients with lamivudine-resistant chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 350-351.

References

[1] 戚敬虎,鞠金昌,徐雷,等.富马酸替诺福韦二吡呋酯单药治疗拉米夫定耐药慢性乙型肝炎的疗效观察.中华肝脏病杂志,2016,24(4):307-309.
[2] 谢巧灵,丛庆伟,吴凌虹,等. 耐核苷(酸)类药物慢性乙型肝炎和肝硬化患者血清HBV基因型和P区耐药突变位点分析. 实用肝脏病杂志,2016,19(1):60-63.
[3] European Association For The Study Of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol,2012,57(1):167-185.
[4] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):V-XVI.
[5] 刘娟,许海波,向天新,等,阿德福韦酯与干扰素联合治疗拉米夫定耐药慢性乙型肝炎临床研究.南昌大学学报(医学版).2013,53(2):51-54.
[6] 曹振环,柳雅立,马丽娜,等. 聚乙二醇干扰素α-2a联合拉米夫定或阿德福韦治疗乙型肝炎e抗原阳性慢性乙型肝炎96周疗效观察. 中华传染病杂志,2016,34(7):422-424.
[7] 柯迎春. 干扰素α治疗拉米夫定耐药慢性乙型肝炎的临床研究. 国际流行病学传染病学杂志,2010,37(4):239-241.
[8] 张骏飞,刘波,杨家宏,等. 拉米夫定治疗乙型肝炎肝衰竭的临床观察,实用肝脏病杂志,2010,12(6):411-413.
[9] 臧玮,田立峰,李萍. 恩替卡韦联合聚乙二醇干扰素α-2a治疗拉米夫定耐药性慢性乙型肝炎的研究进展. 中华临床医师杂志:电子版,2016,5(11):297-298.
[10] 马玉秀. 比较聚乙二醇干扰素α-2a与恩替卡韦治疗慢性乙型肝炎的疗效. 吉林医学,2013,34(3):476-477.
[11] Dogan UB,Golge N,Akin MS.The comparison of the efficacy of pegylated interferon-2a and a-2h in chronic hepatitis B patients.Eur J Gastroenterol Hepatol,2013,25(11):1312-1316.
[12] Xie Q,Zhou H,Bai X,et a1.A randomized,open-label clinical study of combined pegylated interferon alfa-2a(40KD)and entecavir treatment for hepatitis B“e”antigen-positive chronic hepatitis B.Clin Infect Dis,2014,59(12):1714-1723.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

Rescue therapy of pegylated interferon α-2a and entecavir in patients with lamivudine-resistant chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments